Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax (Nasdaq: NVAX) reported second quarter 2026 total revenue of $57 million, down 76% from $239 million a year earlier, mainly due to prior-year milestone and amendment revenue. Product sales were $19 million, up 76% on higher Matrix-M adjuvant demand and partner sales.
GAAP R&D expense was $71 million and SG&A $27 million; Non-GAAP combined R&D and SG&A fell to $74.8 million from $116.4 million. Net loss was $53 million versus net income of $107 million in Q2 2025. Cash, cash equivalents, marketable securities and restricted cash totaled $724 million at June 30, 2026.
Novavax lowered 2026 combined R&D and SG&A guidance by $10 million at the midpoint, maintained Non-GAAP combined expense guidance, and raised its 2026 Adjusted Total Revenue framework to $235–$275 million. The Sanofi partnership continues, with eligibility for up to $125 million in Phase 3 CIC trial initiation milestones, a $75 million manufacturing tech transfer milestone expected upon completion around mid-2027, high-teens to low-twenties royalties on Sanofi global Nuvaxovid sales, and additional Matrix-M–related milestones.
Novavax (Nasdaq: NVAX) will release its second quarter 2026 financial results before U.S. market open on Thursday, August 6, 2026, and will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and operational highlights.
Investors can join via live webcast at ir.novavax.com/events or by phone using U.S. dial-in (+1) 888-880-3330 or international dial-in (+1) 646-357-8766. A replay will be available online and by phone at (+1) 800-770-2030 (U.S.) or (+1) 609-800-9909 (international) with passcode 9097916# starting about two hours after the event.
Novavax (Nasdaq: NVAX) will participate in the 2026 Jefferies Global Healthcare Conference in New York, NY.
The company is scheduled for a fireside chat on Thursday, June 4, 2026, from 10:30–11:00 a.m. Eastern Time. A live webcast and 30-day replay will be available on its investor website.
Novavax (Nasdaq: NVAX) will participate in the BofA Securities 2026 Health Care Conference with a fireside chat on Wednesday, May 13, 2026 at 3:00–3:30 p.m. PT in Las Vegas. A webcast will be available on the company website and a replay will be accessible for 30 days.
Novavax (Nasdaq: NVAX) reported $140 million total revenue for Q1 2026, down 79% year-over-year from $667 million. Licensing, royalties and other revenue totaled $97 million, including a $30 million upfront payment from Pfizer. Net loss was $9 million.
Cash totaled $795 million and Novavax closed a $330 million credit facility. The company reiterated 2026 guidance: Adjusted total revenue $230–$270M and Non-GAAP combined R&D and SG&A $310–$340M.
Novavax (Nasdaq: NVAX) will report first quarter 2026 financial results and operational highlights on May 6, 2026 at 8:30 a.m. ET. A live webcast and conference call will be available, with replay access from 11:30 a.m. ET May 6 through 11:59 p.m. ET May 13, 2026.
Participants may register for automated call-back or dial in directly; the webcast will remain on the investor site through June 6, 2026.
Novavax (NASDAQ: NVAX) appointed Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development effective March 30, 2026. Dr. Walker, a pulmonologist with more than 30 years in drug and vaccine development, previously served as Novavax Chief Medical Officer and will report to CEO John C. Jacobs. He will oversee preclinical and clinical R&D, emphasize data generation to support partnering, and advance Matrix adjuvant innovation and the company pipeline. Dr. Ruxandra Draghia-Akli has departed to pursue other opportunities.
Novavax (Nasdaq: NVAX) will participate in three investor events in March 2026: TD Cowen Health Care Conference (fireside chat, March 3, Boston), Leerink Partners Global Healthcare Conference (fireside chat, March 10, Miami Beach), and Jefferies Biotech on the Beach (investor meetings, March 11, Miami Beach).
A live webcast of the fireside chats will be available at the company’s Events and Presentations page, with replays accessible for 30 days.
Novavax (NASDAQ: NVAX) reported Q4 2025 revenue of $147M and full‑year 2025 revenue of $1.123B. The company earned $225M in Sanofi milestones in 2025 and received a $30M upfront payment from Pfizer in Jan 2026 for a Matrix‑M license. Year‑end cash was $751M and Novavax announced a $330M credit facility in Feb 2026. Management targets reduced combined R&D and SG&A non‑GAAP expense of $310–$340M for 2026 and expects adjusted total revenue of $230–$270M for 2026.
Novavax (Nasdaq: NVAX) will report fourth quarter and full year 2025 financial results and operational highlights on February 26, 2026 at 8:30 a.m. ET.
Investors may join the live conference call by registering for an automated call back or by dialing in; a replay and webcast will be available after the event.